Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | CTSV | O60911 | 2/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16425599 | 0.92 | POLB (0.60) | POLBMEN1KMT2ACTSVCTSL | |
| SCHEMBL12189432 | 0.87 | MRGPRX4 (0.56) | POLBCTSVCTSLMRGPRX4LRRK2 | |
| SCHEMBL12189464 | 0.86 | POLB (0.52) | POLBMEN1KMT2ACTSVCTSL | |
| SCHEMBL12173161 | 0.84 | MEN1 (0.53) | MEN1KMT2ACTSVCTSLMRGPRX4 | |
| SCHEMBL12173124 | 0.84 | MEN1 (0.59) | MEN1KMT2AMRGPRX4EGFRALDH1A1 | |
| SCHEMBL12173118 | 0.81 | MRGPRX4 (0.55) | MEN1KMT2AMRGPRX4EGFRLRRK2 | |
| SCHEMBL12173159 | 0.80 | MRGPRX4 (0.52) | MEN1KMT2AMRGPRX4EGFRLRRK2 | |
| SCHEMBL12173126 | 0.80 | MRGPRX4 (0.53) | MEN1KMT2AMRGPRX4EGFRLRRK2 | |
| SCHEMBL12173117 | 0.80 | MEN1 (0.54) | MEN1KMT2AMRGPRX4EGFRALDH1A1 | |
| SCHEMBL16573839 | 0.80 | POLB (0.69) | POLBMEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150031663-A1 | PHTHALANILATE COMPOUNDS AND METHODS OF USE | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2015-01-29 | — | — | US | disclosed |
| US-8859620-B2 | Phthalanilate compounds and methods of use | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2014-10-14 | — | — | US | disclosed |
| US-20120232150-A1 | PHTHALANILATE COMPOUNDS AND METHODS OF USE | University of Nortre Dame du Lac | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232150-A1 | PHTHALANILATE COMPOUNDS AND METHODS OF USE | MPO, ALPI, NQO1 | POLB 441/4885MEN1 2365/4885KMT2A 1142/4885 |
| US-20150031663-A1 | PHTHALANILATE COMPOUNDS AND METHODS OF USE | MPO, ALPI, NQO1 | POLB 441/4885MEN1 2365/4885KMT2A 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.